Octagam (intravenous normal human immunoglobulin) / Octapharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Octagam (intravenous normal human immunoglobulin) / Octapharma
NCT00812565 / 2007-007134-19: Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Completed
2
58
US
Placebo, octagam 10%, IVIG
Octapharma
Alzheimer's Disease
09/10
09/10
2008-004579-22: A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg Assay Panel and the B-Cell /Antibody response panel to predict the clinical effect of Octagam 5% in subjects with relapsing/remitting (RR) multiple sclerosis (MS)

 
2
21
Europe
Octagam 5%, Octagam 5%, Octagam 5%
Octapharma AG
Subjects with RR Multiple Sclerosis in whom intravenous immunoglobulin (IVIG) treatment is clinically indicated because first-line treatments are contraindicated or not tolerated.
 
03/11
NCT03319810: Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease

Completed
2
5
US
Octagam 10%
Sutter Health
Mild Cognitive Impairment
07/18
07/18
NCT02690038: Ig PRx in AECOPD: Pilot Study

Completed
2
48
Canada
Intravenous immunoglobulin (IVIG), Gamunex, CBS IGIV-nex, Privigen, Octagam, Normal Saline, Saline, Sodium Chloride
Ottawa Hospital Research Institute, CSL Behring, Grifols Biologicals, LLC
Chronic Obstructive Pulmonary Disease
11/19
11/19

Download Options